Authors:
J Wu, VW Keng, DM Patmore, JJ Kendall, AV Patel, E Jousma, WJ Jessen, K Choi, BR Tschida, KAT Silverstein, D Fan, EB Schwartz, JR Fuchs, Y Zou, M-O Kim, E Dombi, DE Levy, G Huang, JA Cancelas, AO Stemmer-Rachamimov, RJ Spinner, DA Largaespada, N Ratner
Journal name: 
Cell Rep
Citation info: 
14(8):1979-1990
Abstract: 
To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and β-catenin activity. β-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and β-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3β and the SWI/SNF gene Arid1b to increase β-catenin. Knockdown of Arid1b or Gsk3β in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/β-catenin pathway inhibitors in neurofibroma therapeutic trials.
DOI: 
http://doi.org/10.1016/j.celrep.2016.01.074
Research group: 
Gilbertson Group
E-pub date: 
29 Feb 2016
Users with this publication listed: 
Deanna Patmore